An internal standard for the quantification of pomalidomide
Related Products
Unlabeled Version(s)
19877Pomalidomide
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Pomalidomide-d5

Item No. 25358

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-amino-2-(2,6-dioxo-3-piperidinyl-3,4,4,5,5-d5)-1H-isoindole-1,3(2H)-dione
CAS Number
1377838-49-7
Molecular Formula
C13H6D5N3O4
Formula Weight
278.3
Purity
≥99% deuterated forms (d1-d5)
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlDMSO: 15 mg/ml
SMILES
NC1=C2C(C(N(C3([2H])C(NC(C([2H])([2H])C3([2H])[2H])=O)=O)C2=O)=O)=CC=C1
InChi Code
InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)/i4D2,5D2,8D
InChi Key
UVSMNLNDYGZFPF-XHNMXOBISA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $401

    Add

    1 mg

    $761

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Pomalidomide-d5 is intended for use as an internal standard for the quantification of pomalidomide (Item No. 19877) by GC- or LC-MS. Pomalidomide is an analog of thalidomide (Item No. 14610) that inhibits the E3 ligase protein cereblon (CRBN) with an IC50 value of approximately 3 µM for the human recombinant CRBN-DNA damage binding protein-1 (CRBN-DDB1) complex.1 It inhibits autoubiquitination of CRBN in HEK293T cells expressing CRBN but not those expressing a thalidomide-binding defective CRBN mutation. It inhibits proliferation of U266 myeloma cells when used at concentrations ranging from 0.1 to 10 µM. Pomalidomide also has antiangiogenic and immunomodulatory effects against myeloma cells, modulating cell adhesion, decreasing production of key pro-survival cytokines, including TNF-α, and triggering the activation of caspase-8.2,3 Pomalidomide (3 mg/kg per day), in combination with dexamethasone, reduces tumor growth in a H929 R10-1 lenalidomide-resistant mouse xenograft model.4 Formulations containing pomalidomide have been used in the treatment of multiple myeloma.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Lopez-Girona, A., Mendy, D., Miller, K., et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26(11), 2326-2335 (2012).

    2. Zhu, Y.X., Kortuem, K.M., and Stewart, A.K. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk. Lymphoma 54(4), 683-687 (2013).

    3. Latif, T., Chauhan, N., Khan, R., et al. Thalidomide and its analogues in the treatment of multiple myeloma. Exp. Hermatol. Oncol. 1(1), 27 (2012).

    4. Rychak, E., Mendy, D., Shi, T., et al. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br. J. Haematol. 172(6), 889-901 (2016).